Copy number variations (CNVs) were found to contribute massively to the variability of genomes. One of the best studied CNV region is the b-defensin cluster (DEFB) on 8p23.1. Individual DEFFB copy numbers (CNs) between 2 and 12 were found, whereas low CNs predispose for Crohn's disease. A further level of complexity is represented by sequence variations between copies (multisite variations, MSVs). To address the relation of DEFB CN and MSV to the expression of b-defensin genes, we analyzed DEFB4 expression in B-lymphoblastoid cell lines (LCLs) and primary keratinocytes (normal human epidermal keratinocyte, NHEK) before and after stimulation with lipopolysaccharide, tumor necrosis factor-a (TNF-a) and interferon-g (IFN-g). Moreover, we quantified one DEFB4 MSV in DNA and mRNA as a marker for variant-specific expression (VSE) and resequenced a region of B2 kb upstream of DEFB4 in LCLs. We found a strong correlation of DEFB CN and DEFB4 expression in 16 LCLs, although several LCLs with very different CNs exhibit similar expression levels. Quantification of the MSV revealed VSE with consistently lower expression of one variant. Costimulation of NHEKs with TNF-a/IFN-g leads to a synergistic increase in total DEFB4 expression and suppresses VSE. Analysis of the DEFB4 promoter region showed remarkably high density of sequence variabilities (B1 MSV/41 bp).
Introduction
Defensins are known to have a role in adapted and innate immunity. They have biocidal effects on bacteria, fungi and viruses, as well as cytokine-like functions. [1] [2] [3] [4] [5] [6] [7] [8] [9] The majority of defensin genes are located on 8p23.1. The region is subdivided in the a-defensin cluster (DEFA), harboring all a-defensin genes, and the b-defensin cluster (DEFB), containing several b-defensin genes. Both clusters are affected by a common copy number variation (CNV) independently of each other. Within DEFA, the CNV unit of 19 kb encompasses DEFA1A3 and the pseudogene DEFTP. [10] [11] [12] [13] [14] However, the 200 kb DEFB varies en bloc in its copy number (CN). 11 Individuals carrying 2-12 copies per diploid genome were found. [11] [12] [13] 15, 16 With respect to size, gene content and numeric variability of DEFB, 8p23.1 represents one of the CNV hotspots in the human genome. Genome-wide CNVs contribute massively to the genetic heterogeneity of humans. Whereas B0.3% of the human genome is covered by single-nucleotide polymorphisms (SNPs), B12% of the human genome is affected by CNVs. 17 It is known that SNPs may affect gene expression and hence determine phenotypes. Very likely, this is also the case for CNVs. 18, 19 Therefore, it is not surprising that the DEFB CNV is associated with clinically important phenotypes. High numbers of DEFB are associated with psoriasis, 20 whereas in the case of Crohn's disease, it is under debate whether low 21 or high CNs 22 are predisposing. Whether and how DEFB CN and expression are correlated is not well known. Considering the gene dosage model, one would expect that transcript level is proportional to CN. This was shown for certain genes on chromosome 21 in patients with Down's syndrome. 23 Recently, a gene dosage effect of FCGR3A was reported for individuals harboring one, two or three copies. 24 For FCGR3B, this effect was also shown for individuals harboring one or two copies. 25, 26 Importantly, low FCGR3B CN is associated with glomerulonephritis in the human autoimmune disease systemic lupus erythematosus, whereas the orthologous rat Fcgr3 gene is a determinant of susceptibility to immunologically mediated glomerulonephritis. 27 In case of b-defensins, Hollox et al. 12 found that the transcript level of DEFB4 is moderately correlated with its CN as determined for seven B-lymphoblastoid cell lines (LCLs). Furthermore, Fellerman et al. 21 found a positive correlation considering DEFB4 transcript level and CN in mucosal specimens obtained from patients suffering from Crohn's disease and ulcerative colitis. A correlation was also observed for the DEFB4 protein (hBD-2) in the serum of healthy individuals but not in psoriasis patients with active disease. 28 However, in patients suffering from inflammatory bowel disease, transcription of DEFB4 is more correlated with disease activity than with the CN. 29 In addition to CNV, sequence variations between copies (multisite variations, MSVs) 30 represent a further level of genomic complexity and are suggested to determine phenotypes, as SNPs do. An association study of DEFB104 and prostate cancer considered both CN and four MSVs (haplotypes thereof) around exon 1.
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Four common haplotypes were found to be associated with the risk of prostate cancer. Moreover, high CNs (49) were significantly underrepresented in both patient samples. This implies a role of both CNs and sequence variations in shaping putative b-defensin-related phenotypes, and therefore MSVs must also to be taken into account when performing b-defensin association studies.
To investigate the relation of DEFB CN and MSVs to the expression of b-defensin genes, we analyzed DEFB4 in LCLs and primary keratinocytes (normal human epidermal keratinocytes, NHEK) before and after stimulation with lipopolysaccharide (LPS), tumor necrosis factor-a (TNF-a) and interferon-g (IFN-g). To investigate whether DEFB4 copies differ in their expression, we quantified a coding MSV in exon 2 as a marker for variant-specific expression (VSE). As nuclear factor (NF)-kB transcription factor-binding sites (TFBSs) upstream of DEFB4 mediate basal and induced expressions, 32 we resequenced a region of B2 kb upstream of the first exon of DEFB4 in LCLs.
We found a strong correlation of DEFB CN and DEFB4 expression in 16 LCLs, although several LCLs with very different CNs exhibit similar expression levels. Quantification of the MSV in DNA and mRNA showed VSE with consistently lower expression of one variant. No induction of DEFB4 expression was detectable in LCLs. In NHEKs, DEFB4 expression can be stimulated using TNF-a or IFN-g. Furthermore, costimulation with TNF-a and IFN-g lead to a synergistic increase in total DEFB4 expression and suppresses VSE. Analysis of the DEFB4 promoter region showed remarkably high sequence variability (B1 MSV/41 bp).
Results
Basal DEFB4 expression in LCLs Among 16 LCLs with DEFB CNs from 2 to 9 determined by multiplex ligation-dependent probe amplification (MLPA), the expression of DEFB4 varied within four orders of magnitude ( Figure 1 ). Among cell lines with the same DEFB CN, the expression varied up to B50-fold. DEFB CN and DEFB4 expressions are significantly correlated (Spearman's rank correlation coefficient r s ¼ 0.77, P ¼ 0.0001) and regression analysis shows an exponential dependency between the two parameters. Nevertheless, 9 out of the 16 LCLs show a very similar DEFB4 expression (between 10-and 100-fold change, r s ¼ 0.43, P ¼ 0.223), although varying in their DEFB CNs from 2 to 7 ( Figure 1 ).
Variant-specific DEFB4 expression in LCLs
To characterize sequence variations that change DEFB4 expression, we quantified as a proxy the silent polymorphism rs2740090 in the protein-coding sequences of DEFB4 exon 2 at both genomic and mRNA levels. Only cell lines were included, which were identified by direct sequencing to differ between copies at this position. Knowing the DEFB CN, the genomic frequency of the variants allows the estimation of the absolute number of copies harboring the respective variant in the respective cell lines (Table 1 ). For instance, in the simplest case, LCL GM12864 harbors two DEFB copies and showed frequencies of 50% for each variant, one DEFB copy contains the C and the other the T variant (similar to a common biallelic locus). Comparative analysis to the chimpanzee genome revealed T as the ancestral variant (UCSC Genome Browser, human genome hg18, chimpanzee genome panTro2). Until now, there is no information in dbSNP 130 about the frequency of the variants in populations. The maximum number of copies harboring the C variant per diploid genome is two and was observed in LCLs with DEFB CNs ranging from 4 to 9. With regard to all LCLs analyzed, the amount of the C variant is 32.8% (C/T 19/ 39). As the cell lines were chosen regarding the DEFB CN, it is questionable whether the observed frequencies of the variants reflect the frequency in human populations. If both variants were transcribed at the same level, one would expect the same C and T fractions in mRNA as in genomic DNA. However, the frequency of the C variant in DEFB4 transcripts is always reduced compared with its genomic occurrence, indicating VSE with C as the less transcribed variant (two-way ANOVA (analysis of variance), Holm-Sidak method, Po0.001, Figure 2) .
Remarkably, the mRNA variant frequency is only weakly correlated with the DEFB4 expression level (r s ¼ 0.25). In relation to the expression of the T variant (100%), the expression of the C variant varies among cell lines from 34 to 83% (Figure 2) . Thereby, the relative expression of the C variant correlates with the DEFB CN (Pearson's product-moment correlation r ¼ 0.66; P ¼ 0.014). 
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Expression of DEFB4 is inducible by LPS, TNF-a and IFN-g. [32] [33] [34] In our experiments, LCLs did not show any increase in DEFB4 expression after treatment (data not shown). Therefore, we switched to NHEKs known to exhibit basal and inducible DEFB4 expressions. 34 Inducible and variant-specific DEFB4 expression in keratinocytes Using four NHEKs, DEFB CNs were determined by MLPA in genomic DNA, and MSV rs2740090 was quantified in both genomic DNA and RNA. DEFB4 expression was analyzed with and without treatment by LPS, TNF-a, IFN-g and a mixture of TNF-a and IFN-g.
In contrast to LCLs, the basal DEFB4 expression in the four NHEKs is weakly correlated with the DEFB CN (r s ¼ 0.4). To check whether this result could be an effect of the small sample size, a permutation test was performed calculating the correlation coefficient of 4 randomly selected out of the 16 LCLs as described in the section 'Materials and methods'. It showed that in In contrast to LPS that did not affect DEFB4 expression (two-way ANOVA, Holm-Sidak method, P ¼ 0.507), the expression of DEFB4 was significantly induced with TNF-a (Po0.001), IFN-g (Po0.001) and with a mixture of TNF-a and IFN-g (Po0.001) (Figure 3) . The induction by TNF-a is higher than by IFN-g. Combined treatment by TNF-a and IFN-g showed a synergistic effect. Furthermore, the expression reached a plateau after induction with a mixture of 20 ng ml À1 TNF-a and 20 ng ml À1 IFN-g and did not increase significantly using 40 þ 20 ng ml DEFB CN and genomic variant distribution of the NHEKs are summed up in Table 1 and Figure 4 . Similar to LCLs, the C variant is consistently lower expressed in NHEKs (between 26 and 66%; two-way ANOVA, Holm-Sidak method, Po0.001). Furthermore, the amount of the C variant in the mRNA does not change after treatment with LPS, TNF-a or IFN-g. The amount of the C variant increases after treatment with a mixture of TNF-a and IFN-g (between 57 and 98%; two-way ANOVA, Holm-Sidak method, Po0.001). With regard to NHEK306 and NHEK707, the relative expression of the C variant increases up to B98%, and therefore the variant specificity is almost abrogated and both variants are equally expressed.
Promoter analysis of DEFB4 To shed further light on sequence variations potentially causative for the observed expression phenotype, we resequenced a 2-kb region upstream of the DEFB4 transcription start site of 9 LCLs, selected from the 16 LCLs analyzed previously. According to DEFB CN data, these 9 LCLs were expected harboring a total of 37 DEFB copies. The samples were chosen to reflect the whole range of DEFB4 expression and DEFB CN. Therefore, LCLs were included harboring the same b-defensin CN, but differ in their DEFB4 expression and vice versa.
The analyzed region contains 43 annotated variations (dbSNP 130). The assembly (hg18) contains two DEFBs flanking a gap (but only in one DEFB4 is annotated). In some cases, different annotations describe the same variation, one in each DEFB. Therefore, some variations have two accession numbers (27 annotations are unique in hg18). Altogether, we identified 49 variations (1/41 bp, 43 single-nucleotide variations, 6 indels) of which 20 confirmed the dbSNP annotations. The applied resequencing strategy and the extraordinary variation density allowed us to unambiguously reconstruct 25 haplotypes ( Figure 5 ). The majority of these haplotypes (20 out of 25) were unique among the 37 DEFB copies. Two haplotypes occur twice, two three times and only one four times. Except for GM18502 (DEFB CN: 9), the number of haplotypes per LCL reflects the DEFB CN, which means that in 8 out of 9 cell lines, each DEFB4 copy harbors a different haplotype.
As defensin expression is mediated by the NF-kB pathway, 35, 36 we checked the analyzed region regarding NF-kB TFBSs. Five potential NF-kB TFBS were found at following positions: chr8
is destroyed (C variant) or created (G variant) by a variation found in five analyzed LCLs (rs2698827). Almost no correlation between the frequency of TFBS (G variant) and relative expression of DEFB4 was found (r s ¼ 0.15). Furthermore, no variation or haplotype could be assigned to or correlated with either high or low DEFB4 expression.
All the four NHEKs are polymorphic for rs2698827. As for the LCLs, we cannot assign the C or G variant either to the total expression or to the inducibility or VSE of DEFB4 (data not shown).
The expression of genes is also regulated by methylation of CpGs. CpGPlot did not show CpG islands within the analyzed region, but 11 out of the 49 variations create or destroy single CpGs. However, no variation was found correlating with high or low expressed DEFB4.
Discussion
Although b-defensins within DEFB are important components of innate immunity, it seems that their variability is an underappreciated source of phenotypic variation. Only few association studies, remarkably designed as candidate gene approaches, have been published. This may in part be due to methodological problems in the characterization of the superimposed types of polymorphisms: structural variation (CNV) and sequence variation (MSV). Although scalable methods to determine CNV in high-throughput screenings lack accuracy, 37 MSVs are resistant to common genotyping. However, both are important to know in order to correlate the genomic state of b-defensins with the phenotypes. CNVs are responsible for different gene dosage in individuals, and MSVs might influence gene expression or mRNA/protein properties.
The observed concordance of DEFB gene numbers 11 means that the CN determined for a one gene or locus serves as a proxy for any other gene/locus of the cluster. However, it is not known whether DEFB MSVs are in linkage equilibrium or whether they are forming only a 
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The study presented herein is an integrated approach, which investigates the DEFB4 expression by regarding both DEFB CN and one MSV (rs2740090). DEFB4 expression was studied in LCLs and NHEKs characterized by their MLPA-determined total DEFB CN subdivided into C and/or T variants. We determined DEFB4 expression by TaqMan assays as basal expression and, in NHEKs only, as stimulated expression after challenging the cells with known DEFB4-inducing agents (such as LPS, TNF-a and IFN-g). The ratios of rs2740090 variants were also determined in DEFB4 transcripts to evaluate their possible differential expression.
In LCLs, we confirmed CN-dependent DEFB4 basal expression (r s ¼ 0.76) 12, 29 in an exponential manner. This was also shown for the expression of DEFB4 and DEFB103 in mucosal specimen. 21 Considering a gene dose-dependent model, one would expect a linear dependency between CN and expression level, as reported for FCGR3B. 25 In hemizygous individuals, half the protein amount was found in the plasma. In contrast, we found that the DEFB4 mRNA expression does not change in a linear but in an exponential manner regarding DEFB CN. AS DEFB is amplified as an entity 39 and each copy of the cluster is flanked by low copy repeats, 16 the exponential dependency might be explained by chromatin remodeling due to stringed arrangement of DEFB copies even cytogenetically visible by fluorescent in situ hybridization. 12 If so, in the future not only the DEFB diplotype has to be taken into account but also the number of DEFB copies per chromosome (genotype). Possible distributions of DEFB copies in one individual sample harboring six DEFBs can be: 1 þ 5, 2 þ 4, 3 þ 3 (we never found an individual sample with one copy, therefore we suggest that the null allele is at least very rare). Furthermore, by comparing original and derived loci in segmental duplication events, Zheng 40 showed that different copies have different histone modifications, which in turn could lead to different expressions of certain copies and consequently to differences in transcript levels.
Among the analyzed 16 LCLs, we identified samples harboring the same DEFB CN, but showing differences in DEFB4 expression, and vice versa, showing similar expression while harboring different DEFB CNs (Figure 1) . Therefore, expression of DEFB4 is not only controlled by CN but also by other factors. DEFB4 expression was not inducible in LCLs. This may be attributable to ligandindependent activation of NF-kB in these cells by EBV proteins, 41 which may result in a permanent induction of DEFB4 expression in this cell lines.
Investigation of MSV rs2740090 in exon 2 of DEFB4 revealed VSE in all analyzed LCLs and in NHEKs. In general, the allele-specific expression (ASE) of a non-CNV biallelic locus, was shown to be widespread in the human genome [42] [43] [44] and associated with disease. 45 Surprisingly, regarding all analyzed cell lines, we found that DEFB4 harboring the C variant is consistently less transcribed. There is no evidence that the analyzed MSV is causative for VSE. We rather suggest a linked variant, which causes the expression difference. Interestingly, the relative expression of the C variant varies in different cell lines more than twofold from 34 to 83%. Furthermore, the relative expression of the C variant correlates with DEFB CN; this means the higher the CN, the lesser the variant specificity during transcription. A possible chromatin remodeling due to stringed arrangement of the DEFB copies may be suspected to affect regulatory elements causative for VSE in the same manner as for CN-dependent DEFB4 expression. With regard to IL10, it was shown that different haplotypes (microsatellites) are strongly associated with differences in interleukin-10 secretion. 46 Expression of a specific variant was also observed regarding KRT1. Cisregulatory SNPs in the promoter region of this gene were found to modulate promoter activity and to cause ASE. 47 Treatment of NHEKs with a mixture of TNF-a and IFN-g (the best stimulus in our hands) led to the suppression of the VSE nearly equalizing the amount of the C variant in the DEFB4 transcripts to those on the genomic level. This may result either from expression saturation of the T variant or preferential induction of the C variant. Such a shift in expression of specific variants was reported in barley hybrids, changing the allelic ratio in some genes after drought stress (for example, ABC02113, ABC03499, ABC10029). 48 To screen for possible cis-regulatory variations causative for total DEFB4 expression or VSE, we resequenced B2 kb upstream of DEFB4 transcription start site in selected cell lines. We found five NF-kB-binding sites in the putative promoter region just upstream of the transcription start. These sites have been described previously and four of them were identified to mediate LPS-induced and basal expressions of DEFB4 in macrophages. 32 Our results do not show any clues for transcription-relevant variations within the TFBS or the complete analyzed region of B2 kb. If there is a variation linked to the consistently lowexpressed C variant that causes VSE, it may not be localized within the analyzed upstream region. In addition to that, because VSE is shifted by costimulation with TNFa and IFN-g, we suggest that there are different regulatory elements for basal and induced DEFB4 expressions. The variant specificity in basal expression will be diminished by regulatory elements that mediate expression by costimulating with TNF-a and IFN-g. This fits to the findings, that cotreatment with TNF-a and IFN-g not only has a synergistic effect on VSE but also on the total DEFB4 transcript level. Such a synergistic effect of DEFB4 expression was previously described by Joly et al. 49 However, they also report that induced expression correlates with basal expression. This is somehow contrary to our results as we found that after stimulation with either TNFa or IFN-g, but not with both cytokines, the induced expression correlates with the basal expression. In agreement with Joly et al., 49 we also found that DEFB4 expression reached a plateau after costimulation with TNF-a and IFN-g, suggesting some kind of saturation. Similar results were also described by Fellermann et al. 21 for DEFB4 expression in mucosa specimen. Taken together, there is a synergistic effect of the mixture of TNF-a and IFN-g on both VSE and total DEFB4 expressions.
As defensins and cytokines that mediate defensin expression are involved in inflammatory diseases, it is not surprising that Aldhous et al. 29 and Jansen et al.
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found that DEFB4 expression reflects the disease activity more than the respective DEFB CN. Therefore, not only cis-but also trans-regulatory elements have to be taken into account when considering DEFB4 expression. In this context, it is of value to possess a sequence tag in DEFB4 (rs2740090), which is associated with a molecular phenotype: One variant (T) shows higher basal expresEffect of CN and sequence variation on DEFB4 expression M Groth et al sion, whereas the other (C) indicates better inducibility. It would be of interest to investigate whether the variant distributions differ in patients suffering from Crohn's disease or psoriasis. Altogether, the basal DEFB4 expression correlates with the DEFB CN, DEFB4 copies harboring the C variant are less expressed than the T variant, and there is a synergistic effect of TNF-a and IFN-g on the VSE and the total DEFB4 expression. Therefore, performing an association study considering DEFB CN and disease with inflammatory background, one has to keep in mind that defensin gene variants seem to be induced differentially. For the future, it would be a challenge to identify sequence variations between copies affecting the induced DEFB4 expression.
Materials and methods
Cells and cell culture Human LCLs were purchased from Coriell Institute for Medical Research (Camden, NJ, USA; naming: GMxxxx) and ECACC (Wiltshire, UK; naming: Cxxxx) ( Table 1) . LCLs were cultured in RPMI 1640 with GlutaMAX (Gibco, Carlsbad, CA, USA) supplemented with 15% fetal bovine serum 'GOLD' (PAA Laboratories, Pasching, Austria) in 25 cm 2 BD Falcon flasks (Becton Dickinson, Franklin Lakes, NJ, USA) at 37 1C in a humidified 5% CO 2 atmosphere in a total volume of 10 ml. Cells were grown to a density of 6 Â 10 5 cells per ml and split in a ratio of 1:4. The cell lines characterized in this study were selected by their DEFB CNs covering the range from 2 to 8 copies, as previously determined by Groth et al.
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NHEKs have been established at the Department of Dermatology using keratinocytes isolated from the foreskins of male infants undergoing routine surgery due to phimosis (circumcision) through enzymatic treatment of the epidermis. 50 Written parental consent was obtained for all patients. NHEKs were cultured in keratinocyte basal medium (PromoCell, Heidelberg, Germany) augmented with Supplement Pack C-39011 (PromoCell) at 37 1C and in a 5% CO 2 atmosphere.
For experiments, the cells were harvested by trypsin-EDTA (Invitrogen, Karlsruhe, Germany) treatment and seeded into 12-well culture plates (Greiner, Frickenhausen, Germany) at a density of 4 Â 10 5 cells per cm 2 . Seventy-two hours after plating, the cell medium was replaced by medium containing LPS (resolved in phosphate-buffered saline, PromoCell) from Salmonella typhimurium (SigmaAldrich, St Louis, MO, USA) at concentration of 1 mg ml Genomic DsNA and mRNA/cDNA Genomic DNA from cell cultures was isolated from 5 Â 10 6 cells using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Total mRNA was isolated using the Qiagen RNeasy Mini Kit (Qiagen) according to the manufacturer's instructions. The isolated mRNAs were reverse transcribed using the High-Capacity cDNA Reverse 

Expression analysis
Determination of transcription level of DEFB4 was performed using TaqMan assays (TaqMan Gene Expression Assay and TaqMan Gene Expression Mastermix) purchased from Applied Biosystems. The reactions were performed in 96-well PCR plates (Bio-Rad Laboratories, Hercules, CA, USA) according to the manufacturer's instructions using an iCycler instrument (Bio-Rad Laboratories). The following TaqMan Gene Expression Assays were used: ACTB (Hs99999903_m1), DEFB4 (00823638_m1) and TBP (99999910_m1). All reactions were performed at least in triplicates. Relative DEFB4 expression was determined as described previously. 51 Variant-specific transcription PCR was performed with primers flanking rs2740090 on genomic DNA and cDNA. Amplification of genomic DNA was carried out with 50 ng DNA template in a volume of 25 ml using BioMix Red (Bioline, Luckenwalde, Germany) according to the manufacturer's instructions using forward primer 5 0 -GGCGATACTGACACAGGG TT-3 0 and reverse primer 5 0 -GGCGATACTGACACAGG GTT-3 0 . The amplification of cDNA was performed under the same conditions using forward primer 5 0 -ATCAGCC ATGAGGGTCTTGT-3 0 and reverse primer 5 0 -TTTGGTTT ACATGTCGCACG-3 0 . Quantification of rs2740090 variants was performed using a pyrosequencing approach as described previously 39 using sequencing primer 5 0 -GTGTTTTTGGTGGTATAGGCGA-3 0 on a PSQ 96 MA System (Qiagen).
DEFB4 promoter analysis Genomic DNA of 2 kb upstream of exon 1 of DEFB4 (chr8: 7 787 620-7 789 657; chr8: 7 261 747-7 263 787, UCSC Genome Browser, human genome hg18 52 ) was amplified using the primers 5 0 -AATGGAAGCATTTCTGTGGG-3 0 and 5 0 -ACAAGACCCTCATGGCTGAT-3 0 . PCR was performed in a volume of 25 ml using BioMix Red (Bioline) according to the manufacturer's instructions. Direct sequencing of the amplicons failed due to insertions/ deletions located in the analyzed region. In contrast to Aldhous et al., 29 we therefore performed a cloning/ sequencing-based approach. The amplicon was cloned using the TA Cloning Kit (with pCR 2.1 vector) (Invitrogen) according to the manufacturer's instructions. Depending on the DEFB CN of the respective individual sample, certain numbers of clones were sequenced (see Table 1 ) using two primers located within the amplicon (forward primer 5 0 -ATGAAGAGGTCAG GCAGGTC-3 0 , reverse primer 5 0 -GAAGGAGAATGGGA GGATGG-3 0 ) and vector-specific M13 primers. To avoid false-positive variations, the number of clones to sequence was chosen on the basis of the assumption that at least 10 clones have to represent the amplified region from one copy, meaning that DEFB CN times 10 was the least number of clones to sequence. The resulting sequences were manually inspected for variations using Genome Assembly Program 4 53 and analyzed for TFBS using Transcription Element Search System 54 and CpG islands using EMBOSS CpGPlot. 55 
Statistic analysis
All statistics were performed using SigmaPlot 11 (Systat Software Inc., Erkrath, Germany). A permutation test for calculating the possibility of finding a correlation with four LCLs was performed as follows. Data (DEFB CN and DEFB4 expression) of four LCLs were chosen randomly from the set of 16 LCLs. Spearman's rank correlation was calculated for this subset and this procedure (data selection, correlation test) was performed one million times. The frequency of correlation coefficients reaching a threshold (r s of the four NHEKs) reflects the statistical power of the experiment using only four cell lines.
